Dawn Nolt, M.D., joined Elnahal at the event to urge people to take preventive measures to protect themselves and others from respiratory illness.

Dawn Nolt, M.D., joined Elnahal at the event to urge people to take preventive measures to protect themselves and others from respiratory illness.

At his monthly media availability, Shereef Elnahal, M.D., voices concerns about potential cuts to the 340-B program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients.

Amid an outbreak of infant botulism caused by Byheart baby formula, Dawn Nolt, M.D., advises parents to contact their child’s clinician if their infant has consumed Byheart formula and is experiencing symptoms of botulism: “It causes profound weakness, constipation, difficulty swallowing, and so even though infant botulism is quite rate, it certainly is a very serious disease.”

At his monthly media availability, Shereef Elnahal, M.D., voices concerns about potential cuts to the 340-B program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients.

OHSU researchers have developed a new molecule that offers a promising avenue to treat intractable cases of triple-negative breast cancer. Sanjay Malhotra, Ph.D., says, “We're very excited. The good part is it is not at the discovery stage. Discovery is already done, and discovery has led to this exciting outcome. Now it's at the development stage, which is where we need resources to bring it to clinic."

Bloomberg TV’s Wall Street Week reports on the broken state of pediatric health care financing. Ben Hoffman, M.D., explains that insurance payment structures reimburse pediatric health care services at significantly lower rates than adult services, which inherently puts children at a disadvantage: “Children are 30% of our population but 100% of our future … Cobbling together something with the crumbs or what’s left over from the adult system is just not going to work.”

OHSU researchers have developed a new molecule that offers a promising avenue to treat intractable cases of triple-negative breast cancer. Sanjay Malhotra, Ph.D., says, “We're very excited. The good part is it is not at the discovery stage. Discovery is already done, and discovery has led to this exciting outcome. Now it's at the development stage, which is where we need resources to bring it to clinic."

OHSU researchers have developed a new molecule that offers a promising avenue to treat intractable cases of triple-negative breast cancer. Sanjay Malhotra, Ph.D., says, “We're very excited. The good part is it is not at the discovery stage. Discovery is already done, and discovery has led to this exciting outcome. Now it's at the development stage, which is where we need resources to bring it to clinic."

Claudia Aime, D.N.P., RN, chief nursing officer at OHSU, is recognized as one of the top 50 leaders of Portland for 2025.